Lv1
100 积分 2024-02-28 加入
Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy
17小时前
已完结
Membrane‐Fusion‐Mediated Multiplex Engineering of Tumor Cell Surface Glycans for Enhanced NK Cell Therapy
5个月前
已完结
Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader
7个月前
已完结
Targeted protein degradation via cellular trafficking of nanoparticles
7个月前
已完结
Abstract CT257: First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors
7个月前
已关闭
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer
11个月前
已完结
Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer
11个月前
已完结
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
11个月前
已完结
A review of design criteria for cancer-targeted, nanoparticle-based MRI contrast agents
1年前
已完结
皖公网安备34019202002308
